EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Spero Therapeutics's Enterprise Value is €5.87 Mil.
Spero Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-30.27 Mil. Therefore, Spero Therapeutics's EV-to-FCF for today is -0.19.
The historical rank and industry rank for Spero Therapeutics's EV-to-FCF or its related term are showing as below:
STU:2HA'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.39 Med: -1.91 Max: 4.66
Current: -0.19
During the past 9 years, the highest EV-to-FCF of Spero Therapeutics was 4.66. The lowest was -8.39. And the median was -1.91.
STU:2HA's EV-to-FCF is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 4.3
vs STU:2HA: -0.19
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Spero Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spero Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Spero Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's EV-to-FCF falls into.
Spero Therapeutics's current Enterprise Value is €5.87 Mil.
Spero Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-30.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Spero Therapeutics's PE Ratio for today is calculated as:
Spero Therapeutics's share price for today is €1.32.
Spero Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.388.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Spero Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Spero Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:2HA has been successfully added to your 